The ASCO Post Podcast

This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.Coverage of stories discussed this week on ascopost.com:Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon CancerRisk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone DiseaseTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition. This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.Coverage of stories discussed this week on ascopost.com:Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon CancerRisk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone DiseaseTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com: This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.Coverage of stories discussed this week on ascopost.com:Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon CancerRisk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone DiseaseTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.Coverage of stories discussed this week on ascopost.com:Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon CancerRisk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone DiseaseTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we’re featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we’re featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.

This week, we’ll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.

The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We’re featuring three studies on the podcast this week from the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We’re featuring three studies on the podcast this week from the meeting.

As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.Coverage of stories discussed this week on ascopost.com:Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for CancerSurvey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 PandemicTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials. As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.Coverage of stories discussed this week on ascopost.com:Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for CancerSurvey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 PandemicTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com: As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.Coverage of stories discussed this week on ascopost.com:Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for CancerSurvey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 PandemicTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.Coverage of stories discussed this week on ascopost.com:Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for CancerSurvey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 PandemicTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic

This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.Coverage of stories discussed this week on ascopost.com:Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With ImmunotherapyTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment. This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.Coverage of stories discussed this week on ascopost.com:Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With ImmunotherapyTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com: This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.Coverage of stories discussed this week on ascopost.com:Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With ImmunotherapyTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy

This week, we're focusing on high-impact research in prostate cancer presented during the virtual 2020 ASTRO Annual Meeting. The studies included a focus on GnRH receptor antagonist therapy; imaging-based guidance for radiotherapy intensification; and methods of radiotherapy boosts.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're focusing on high-impact research in prostate cancer presented during the virtual 2020 ASTRO Annual Meeting. The studies included a focus on GnRH receptor antagonist therapy; imaging-based guidance for radiotherapy intensification; and methods of radiotherapy boosts.

This week, we’ll be featuring discussions of two late-breaking abstracts presented during the virtual 2020 American Society for Radiation Oncology, or ASTRO, Annual Meeting. The first focuses on the role of imaging to plan treatment with radiotherapy in patients with prostate cancer. The second discusses strategies to manage the pain of spinal metastases. To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll be featuring discussions of two late-breaking abstracts presented during the virtual 2020 American Society for Radiation Oncology, or ASTRO, Annual Meeting. The first focuses on the role of imaging to plan treatment with radiotherapy in patients with prostate cancer. The second discusses strategies to manage the pain of spinal metastases. 

This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.Coverage of stories discussed this week on ascopost.com:FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AMLFDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin LymphomaTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively. This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.Coverage of stories discussed this week on ascopost.com:FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AMLFDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin LymphomaTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com: This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.Coverage of stories discussed this week on ascopost.com:FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AMLFDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin LymphomaTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AML This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.Coverage of stories discussed this week on ascopost.com:FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AMLFDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin LymphomaTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin Lymphoma

This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.Coverage of stories discussed this week on ascopost.com:First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression. This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.Coverage of stories discussed this week on ascopost.com:First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com: This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.Coverage of stories discussed this week on ascopost.com:First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110 This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.Coverage of stories discussed this week on ascopost.com:First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?

This week, we’ll be featuring our last disease-specific roundup from the ESMO Virtual Congress 2020. We’ll hear from three experts on their findings in breast cancer, focusing on results from two IMpassion trials as well as the efficacy of a novel antibody-drug conjugate in triple-negative disease, and a telehealth program for patients receiving chemotherapy.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll be featuring our last disease-specific roundup from the ESMO Virtual Congress 2020. We’ll hear from three experts on their findings in breast cancer, focusing on results from two IMpassion trials as well as the efficacy of a novel antibody-drug conjugate in triple-negative disease, and a telehealth program for patients receiving chemotherapy.

This week, we’ll be reviewing results from several reports on lung cancer presented during the ESMO Virtual Congress 2020. The findings focus on the use of radiotherapy, biomarkers, targeted treatments, and immunotherapy.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll be reviewing results from several reports on lung cancer presented during the ESMO Virtual Congress 2020. The findings focus on the use of radiotherapy, biomarkers, targeted treatments, and immunotherapy.

This week, we’re hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We’ll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We’ll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.  

This weekend, the ESMO Virtual Congress 2020 is underway, and we’re sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presented at the event.To listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This weekend, the ESMO Virtual Congress 2020 is underway, and we’re sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presented at the event.  

We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer. We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com: We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 Trial We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Pralsetinib for Metastatic RET We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Fusion–Positive NSCLC We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> To listen to more podcasts from ASCO, visit asco.org/podcasts